Protein level may predict immunotherapy success in four cancers
NCT ID NCT07485114
First seen Mar 28, 2026 · Last updated May 06, 2026 · Updated 4 times
Summary
This study is for people with kidney, bladder, lung, or liver cancer who are about to start immunotherapy (PD-1/PDL-1 inhibitors). Researchers want to see if levels of a protein called Galectin-3 in the blood are linked to how well the treatment works and what side effects occur. About 300 participants will give blood samples before each treatment session over three years. The goal is to learn if Galectin-3 can help predict outcomes and guide better use of immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tel Aviv Sourasky Medical Center
RECRUITINGTel Aviv, Israel, 64239, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.